Immune system modulation via repeated exposure to specific allergens

"Immune system modulation via repeated exposure to specific allergens" refers to the process underlying allergen-specific immunotherapy. This is not a single molecular target but rather a therapeutic approach that aims to induce immune tolerance by administering gradually increasing doses of an allergen. The goal is to shift the immune response away from pathogenic allergy-promoting pathways toward regulatory or non-reactive states. Mechanistically, this involves several coordinated changes within the immune system: • **Antigen-presenting cells** present allergens on MHC class II molecules, activating helper T cells. • In allergic individuals, this typically leads to differentiation into Th2 cells and production of cytokines like IL‑4, IL‑5, and IL‑13—driving B-cell class switching toward IgE production. • Repeated controlled exposure can instead promote expansion or activation of **regulatory T cells** (Tregs), which secrete anti-inflammatory cytokines such as IL‑10 and TGF‑β. These suppress effector responses against the allergen.[2] • There is also increased production of "blocking" antibodies like **IgG4**, which can intercept allergens before they bind IgE on mast cells/basophils.[3] This reduces degranulation events responsible for acute allergy symptoms.[1][3] This approach is used clinically for conditions such as allergic rhinitis, asthma due to inhaled allergens, venom allergies, and some food allergies. Because "immune system modulation via repeated exposure..." describes a therapeutic strategy rather than a discrete molecule/receptor/protein/gene family member commonly considered a drug target in pharmacology or molecular biology databases—and because it encompasses multiple cellular/molecular targets—it should not be classified as a canonical molecular target. > The process involves complex interactions between antigen-presenting cells, helper/regulatory T lymphocytes (especially Foxp3+ regulatory T-cells), B-cells producing various antibody classes including IgE/IgG4/IgA/IgM depending on context; effector granulocytes like mast cells/eosinophils/basophils; epithelial-derived cytokines; among others.[1][2][3] Therefore: • It does not have a standard abbreviation. • It is not itself considered a single therapeutic target but rather describes an *immunological mechanism* involving multiple targets. • If you are seeking structured information about individual molecules involved—such as "high-affinity Fc epsilon receptor I", "interleukin 10", "Foxp3+ regulatory T cell", etc.—those should be listed separately with their own canonical names. If you need information about one specific molecule within this pathway—for example “Regulatory T cell” or “Fc epsilon receptor I”—please specify so structured data can be provided accordingly.

Other names

Allergen-specific immunotherapyAllergen desensitizationImmune tolerance induction (via allergen exposure)

Induction of regulatory T cells (Tregs) that suppress allergic inflammation[2] - Shift from Th2 to Th1 immune response[2] - Increased production of blocking antibodies such as IgG4[3] - Suppression of mast cell and basophil activation by reducing IgE-mediated degranulation[1][3]